24 institutions hold shares in Purple Biotech Ltd. (PPBT), with 329.2k shares held by insiders accounting for 1.88% while institutional investors hold 25.34% of the company’s shares. The shares outstanding are 17.51M, and float is at 16.24M with Short Float at 1.50%. Institutions hold 24.87% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Morgan Stanley with over 0.49 million shares valued at $1.88 million. The investor’s holdings represent 2.83% of the PPBT Shares outstanding. As of Dec 30, 2020, the second largest holder is Orbimed Advisors LLC. with 0.35 million shares valued at $1.32 million to account for 1.98% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.13 million shares representing 0.74% and valued at over $0.49 million, while Susquehanna Fundamental Investments, LLC holds 0.16% of the shares totaling 28800.0 with a market value of $0.11 million.
Purple Biotech Ltd. (NASDAQ: PPBT) is 22.31% higher on its value in year-to-date trading and has touched a low of $2.79 and a high of $14.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PPBT stock was last observed hovering at around $4.36 in the last trading session, with the day’s gains setting it 0.3% off its average median price target of $25.00 for the next 12 months. It is also 81.36% off the consensus price target high of $25.00 offered by 1 analysts, but current levels are 81.36% higher than the price target low of $25.00 for the same period.
Currently trading at $4.66, the stock is 11.90% and -1.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.56 million and changing 6.88% at the moment leaves the stock -5.42% off its SMA200. PPBT registered 51.00% gain for a year compared to 6-month gain of 6.88%. The firm has a 50-day simple moving average (SMA 50) of $4.7076 and a 200-day simple moving average (SMA200) of $4.4212.
The stock witnessed a 1.53% loss in the last 1 month and extending the period to 3 months gives it a 2.87%, and is 14.78% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.87% over the week and 6.44% over the month.
Purple Biotech Ltd. (PPBT) has around 13 employees, a market worth around $81.60M and $1.00M in sales. Distance from 52-week low is 66.91% and -67.64% from its 52-week high.
Purple Biotech Ltd. (PPBT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Purple Biotech Ltd. (PPBT) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Purple Biotech Ltd. is expected to release its quarterly report on 08/18/2021 and quarterly earnings per share for the current quarter are estimated at $0..